$90.89
-0.033%Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through Medical and Non-Medical segments. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; and arthroscopic, laparoscopic, and general surgery devices and components, such as harmonic scalpels, shaver blades, burr shavers, radio frequency probes, biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment components, and phacoemulsification needles. Further, it provides orthopedic products that include instruments used in hip, knee, and spine surgeries, as well as reamers and chisels. Additionally, the company offers customized battery power and power management systems, and battery solutions for the energy, military, and environmental markets. Furthermore, the company provides medical technologies. It serves multi-national original equipment manufacturers and their affiliated subsidiaries in the cardiac, neuromodulation, orthopedics, vascular, and advanced surgical and portable medical markets. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.
Wall Street analysts project that ITGR stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 103.67, with estimates ranging from a low of 95.00 to a high of 115.00.
The consensus 1-year price target stands at 103.67, with estimates ranging from a low of 95.00 to a high of 115.00.
Moderate upside. Analysts expect positive returns but with limited margin of safety. Consider entry timing.
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Declining expectations indicate headwindsโinvestigate whether temporary or structural issues.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
Declining expectations indicate headwindsโinvestigate whether temporary or structural issues.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Declining expectations indicate headwindsโinvestigate whether temporary or structural issues.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Mixed signalsโsome positive indicators offset by concerns about growth or uncertainty.
Strong growth expectations signal robust business momentum and market opportunity expansion.
Moderate coverageโsufficient for guidance but may lack depth of large-cap analysis.
Narrow estimate range signals strong analyst consensus and predictable business outlook.
Positive analyst consensus with strong growth expectations and forecast confidence.
Compelling growth story with analyst consensus: Strong projected growth combined with narrow estimate spread suggests high-conviction opportunity.
During the last 12 months, insiders have purchased $500K and sold $132K worth of ITGR shares, resulting in $368K of net buying activity.
0
0.00
825
70.12K
-70K
-$70K
0
0.00
0
0.00
+0
+$0
7.5K
500.20K
884
62.01K
+438K
+$438K
0
0.00
0
0.00
+0
+$0
Khales Payman
Director, Officer: President & Ceo
$203K
Harris John A
Officer: Evp, Global Ops And Manufactur
$116K
Capps Cheryl C
Director
$107K
Smith Diron
Officer: Evp, Chief Financial Officer
$75K
Thomas Tommy P
Officer: Vp, Corporate Controller
$132K
Strong bullish signal with $368K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Exceptional buy/sell ratio. Buying dramatically outweighs sellingโone of the strongest possible insider signals.
Heavy recent selling activity. Recent insider sales notably exceed purchasesโmay warrant investigation into company developments.
4 insider buyers vs. 1 sellers. Broad-based buying across management team suggests widespread confidence.
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
Continue your ITGR research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.